Hot off the Press: VIVUS Earnings Report

VIVUS  (Nasdaq: VVUS  ) has made a habit of being first. Its obesity drug Qsymia was the first weight-loss drug to hit the market in 13 years. It's also the first of three high profile obesity-focused stocks reporting earnings this quarter, with third-quarter results released this morning. The others, Arena Pharmaceuticals (Nasdaq: ARNA  ) and Orexigen Therapeutics (Nasdaq: OREX  ) , report after the market closes today and tomorrow, respectively.

With sales of only $40,000 last quarter, VIVUS' revenue line looks more like your local delicatessen than a company with a $1.5 billion market cap. That revenue number came in well below the average analyst estimate of $350,000, as did the net loss per share of $0.40 (estimates called for a $0.34 loss). But with the company's potential blockbuster Qsymia only available to patients since mid-September, this quarter's financial results shouldn't be the top concern.

The VIVUS investment thesis revolves around future expectations, and Qsymia sales will undoubtedly take some time to ramp up. But how long will it take for sales to ramp? What is the ultimate revenue opportunity? Unfortunately, there was no commentary around future expectations on today's earnings release. Investors will have to wait until the company's earnings call later this morning for additional color. 

In the meantime, make sure you understand the full story behind VIVUS by picking up a copy of the Fool's brand new premium research report. It's a story so important we have our top health care writer on the job, so make sure to secure a copy today by clicking here now.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2097435, ~/Articles/ArticleHandler.aspx, 9/16/2014 11:43:19 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement